Elms Steven A.'s most recent trade in Adma Biologics Inc was a trade of 194,749 Common Stock done at an average price of $20.2 . Disclosure was reported to the exchange on June 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Adma Biologics Inc | Steven A. Elms | Director | Sale of securities on an exchange or to another person at price $ 20.24 per share. | 12 Jun 2025 | 194,749 | 87,330 (0%) | 0% | 20.2 | 3,941,720 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Sale of securities on an exchange or to another person at price $ 20.82 per share. | 12 Jun 2025 | 137,931 | 282,079 (0%) | 0% | 20.8 | 2,871,723 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Sale of securities on an exchange or to another person at price $ 21.69 per share. | 12 Jun 2025 | 92,941 | 2,031,730 (2%) | 0% | 21.7 | 2,015,890 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 55,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.35 per share. | 12 Jun 2025 | 55,000 | 277,667 (0%) | 0% | 2.4 | 129,250 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 53,837 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.66 per share. | 12 Jun 2025 | 53,837 | 160,167 (0%) | 0% | 3.7 | 197,043 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 53,172 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.67 per share. | 12 Jun 2025 | 53,172 | 330,839 (0%) | 0% | 1.7 | 88,797 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 51,630 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.35 per share. | 12 Jun 2025 | 51,630 | 382,469 (0%) | 0% | 3.4 | 172,961 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 37,541 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.40 per share. | 12 Jun 2025 | 37,541 | 420,010 (0%) | 0% | 5.4 | 202,721 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.89 per share. | 12 Jun 2025 | 30,000 | 207,667 (0%) | 0% | 3.9 | 116,700 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 17,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.91 per share. | 12 Jun 2025 | 17,500 | 177,667 (0%) | 0% | 4.9 | 85,925 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 15,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.92 per share. | 12 Jun 2025 | 15,000 | 222,667 (0%) | 0% | 2.9 | 43,725 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.00 per share. | 12 Jun 2025 | 10,000 | 106,330 (0%) | 0% | 5 | 50,000 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jun 2025 | 9,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.96 per share. | 12 Jun 2025 | 9,000 | 96,330 (0%) | 0% | 6.0 | 53,640 | Common Stock |
| Elevation Oncology Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 16,279 | 16,279 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2025 | 10,889 | 87,330 (0%) | 0% | 0 | Common Stock | |
| Marker Therapeutics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Marker Therapeutics Inc | A. Elms Steven | Director | Purchase of securities on an exchange or from another person at price $ 3.20 per share. | 23 Dec 2024 | 11,085 | 325,370 (0%) | 0% | 3.2 | 35,472 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.80 per share. | 27 Nov 2024 | 9,000 | 2,124,671 (2%) | 0% | 10.8 | 97,200 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Nov 2024 | 9,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Elevation Oncology Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2024 | 35,000 | 35,000 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Sale of securities on an exchange or to another person at price $ 6.08 per share. | 18 Mar 2024 | 411,829 | 2,115,671 (2%) | 0% | 6.1 | 2,503,920 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 18 Mar 2024 | 49,887 | 2,527,500 (2%) | 0% | 6.0 | 299,821 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Sale of securities on an exchange or to another person at price $ 6.05 per share. | 13 Mar 2024 | 448,276 | 2,760,395 (3%) | 0% | 6.1 | 2,712,070 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Sale of securities on an exchange or to another person at price $ 6.21 per share. | 13 Mar 2024 | 407,000 | 3,208,671 (3%) | 0% | 6.2 | 2,527,470 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Sale of securities on an exchange or to another person at price $ 6.01 per share. | 13 Mar 2024 | 183,008 | 2,577,387 (2%) | 0% | 6.0 | 1,099,878 | Common Stock |
| Adma Biologics Inc | Elms Steven A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 37,541 | 37,541 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Elms Steven A. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2024 | 24,040 | 76,441 (0%) | 0% | 0 | Common Stock | |
| Marker Therapeutics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2023 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 51,630 | 51,630 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 25,815 | 52,401 (0%) | 0% | 0 | Common Stock | |
| Marker Therapeutics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2022 | 80,000 | 80,000 | - | - | Stock Option (Right to Buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 53,172 | 53,172 | - | - | Employee Stock Option (right to buy) | |
| Adma Biologics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2022 | 26,586 | 26,586 (0%) | 0% | 0 | Common Stock | |
| Marker Therapeutics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jun 2021 | 12,658 | 29,680 (0%) | 0% | 0 | Common Stock | |
| Marker Therapeutics Inc | Steven A. Elms | Director | Purchase of securities on an exchange or from another person at price $ 1.75 per share. | 16 Mar 2021 | 1,142,857 | 3,142,857 (6%) | 2% | 1.8 | 2,000,000 | Common Stock |
| Adma Biologics Inc | Steven A. Elms | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2021 | 55,000 | 55,000 | - | - | Stock Option (right to buy) |